Skip to main content
SpringerLink
Log in

Overview and the Future of Obesity Treatment

  • Chapter
The Management of Eating Disorders and Obesity

Part of the book series: Nutrition and Health ((NH))

Abstract

This chapter addresses the future of obesity treatment. To provide a foundation for discussing the future, we begin with a brief background on the importance of obesity treatment and review of current interventions. We then examine issues and controversies that we believe will affect the future of obesity treatment including the relevance of body mass index (BMI) to healthy weight, the impact of short-term weight changes and normalization of comorbid conditions on long-term health, the cost-effectiveness and feasibility of continuous care to improve weight-loss maintenance, the shift toward more comprehensive health models in obesity treatment, and promising directions in the prevention of obesity. Table 1 overviews the organization of the chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Flegal, KM, Carroll, MS, Ogden, CL, Johnson, CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288:1723–1727.

    Article  Google Scholar 

  2. Denke MA, Sempos CT, Grundy SM. Excess body weight: an under-recognized contributor to dyslipidemia in White American women. Arch Intern Med 1994; 154:401–410.

    Article  CAS  Google Scholar 

  3. Denke MA, Sempos CT, Grundy SM. Excess body weight: an under-recognized contributor to high blood cholesterol levels in White American women. Arch Intern Med 1993; 153:1093–1103.

    Article  CAS  Google Scholar 

  4. MacMahon S, Cutler J, Brittain E, et al. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987; 8(Suppl B):57–70.

    Google Scholar 

  5. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000; 160:898–904.

    Article  Google Scholar 

  6. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119:655–660.

    CAS  Google Scholar 

  7. Solomon CG, Willett WC, Manson JE. Body weight and mortality. In: VanItallie TB, Simonpoulos AP, eds. Obesity: New directions in assessment and management. Charles Press, Philadelphia, PA, 1995, pp. 1–11.

    Google Scholar 

  8. Troiano RP, Frongillo EA Jr, Sobal J, et al. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord 1996; 20:63–75.

    CAS  Google Scholar 

  9. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333:677–685.

    Article  CAS  Google Scholar 

  10. Allison, DB, Fontaine, KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999; 282:1530–1538.

    Article  CAS  Google Scholar 

  11. Wolf A. Economic outcomes of the obese patient. Obesity Res, 2002; 10:58S–62S.

    Google Scholar 

  12. Finkelstein E, Fiebelkorn I, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Affairs 2003; W3:219–226.

    Google Scholar 

  13. Pronk N, Goodman M, O’Connor P, Martinson B. Relationship between modifiable health risks and short-term health care charges. JAMA 1999; 282:2235–2239.

    Article  CAS  Google Scholar 

  14. Sjöström L, Narbro, K, Sjöström D. Costs and benefits when treating obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl 6):S9–S12.

    Google Scholar 

  15. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Affairs 2002; 21:245–253.

    Article  Google Scholar 

  16. Thompson D, Wolf A. The medical-care cost burden of obesity. Obes Rev 2001; 2:189–197.

    Article  CAS  Google Scholar 

  17. Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993; 329:1008–1012.

    Article  CAS  Google Scholar 

  18. Enzi G. Socioeconomic consequences of obesity: the effect of obesity on the individual. Pharmaco Econom 1994; 5(Suppl 1):54–57.

    CAS  Google Scholar 

  19. Sarlio-Lähteenkorva S, Stunkard AJ, Rissanen A. Psychosocial factors and quality of life in obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl 6):S1–S5.

    Google Scholar 

  20. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56:320–328.

    CAS  Google Scholar 

  21. Kanders BS, Blackburn GL. Reducing primary risk factors by therapeutic weight loss. In: Wadden TA, VanItallie TB, eds. Treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 213–230.

    Google Scholar 

  22. Foreyt JP, Goodrick GK. Attributes of successful approaches to weight loss and control. Appl Prev Psychol 1994; 3:209–215.

    Article  Google Scholar 

  23. Perri MG, Fuller PR. Success and failure in the treatment of obesity: where do we go from here? Medicine, Exercise, Nutrition, and Health 1995; 4:255–272.

    Google Scholar 

  24. Stunkard AJ. An overview of current treatments for obesity. In: Wadden TA, VanItallie TB, eds. Treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 33–43.

    Google Scholar 

  25. Wadden TA, Brownell KD, Foster GD. Obesity: Responding to the global epidemic. J Consult Clin Psychol 2002; 70:510–525.

    Article  Google Scholar 

  26. Kramer FM, Jeffery RW, Forster JL, et al. Long-term follow-up of behavioral treatment for obesity: patterns of weight gain among men and women. Int J Obes Relat Metab Disord 1989; 13:124–136.

    Google Scholar 

  27. Stalonas PM, Perri MG, Kerzner AB. Do behavioral treatments of obesity last? a five-year follow-up investigation. Addict Behav 1984; 9:175–184.

    Article  CAS  Google Scholar 

  28. Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet, behavioral therapy, and their combination: a five-year perspective. Int J Obes Relat Metab Disord 1989; 13(Suppl 2):39–46.

    Google Scholar 

  29. Perri MG, Nezu AM, Viegener BJ. Improving the long-term management of obesity: theory, research, and clinical guidelines. Wiley, New York, NY, 1992, pp. 3–124.

    Google Scholar 

  30. Lee I, Blair S, Allison D, et al. Epidemiologic data on the relationships of caloric intake, energy balance, and weight gain over the life span with longevity and morbidity. Journals of Gerontology: SERIES A 2001; 56A:7–19.

    Google Scholar 

  31. Perri MG, Shapiro RM, Ludwig WW, et al. Maintenance strategies for the treatment of obesity: an evaluation of relapse prevention training and posttreatment contact by mail and telephone. J Consult Clin Psychol 1984; 52: 404–413.

    Article  CAS  Google Scholar 

  32. Perri MG, McAdoo, WG, McAllister DA, et al. Effects of peer support and therapist contact on long-term weight loss. J Consult Clin Psychol 1987; 55:615–617.

    Article  CAS  Google Scholar 

  33. Perri MG, McAllister DA, Gange JJ, et al. Effects of four maintenance programs on the long-term management of obesity. J Consult Clin Psychol 1988; 56:529–534.

    Article  CAS  Google Scholar 

  34. Baum JG, Clark HB, Sandler J. Preventing relapse in obesity through posttreatment maintenance systems: comparing the relative efficacy of two levels of therapist support. J Behav Med 1991; 14:287–302.

    Article  CAS  Google Scholar 

  35. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119:707–713.

    CAS  Google Scholar 

  36. Haddock C, Poston W, Dill P, Foreyt J, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 2002; 26:262–273.

    Article  CAS  Google Scholar 

  37. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. JAMA 1996; 335:609–616.

    CAS  Google Scholar 

  38. Centers for Disease Control (CDC). Cardiac valvulopathy associated with fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR 1997; 46:1061–1066.

    Google Scholar 

  39. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581–588.

    Article  CAS  Google Scholar 

  40. Stunkard AJ, Harris JR, Pederson NL, et al.The body mass of twins reared apart. N Engl J Med 1990; 322:1483–1487.

    Article  CAS  Google Scholar 

  41. Kahn L, Serdula M, Bowman B, Williamson D. Use of prescription weight loss pills among U.S. adults in 1996–1998. Ann Intern Med 2001; 134:282–286.

    Google Scholar 

  42. National Institutes of Health (National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Disease), Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults 1998. NIH Publication No. 98-4083. US Government Printing Office, Washington, DC.

    Google Scholar 

  43. Phelan S, Wadden T. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002; 10:560–574.

    Google Scholar 

  44. Frost GL, Bovill-Taylor C, Carter L, et al. Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese. J Hum Nutr Diet 2002; 15:287–295.

    Article  CAS  Google Scholar 

  45. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002; 26:S29–33.

    Article  CAS  Google Scholar 

  46. Wadden T, Berkowitz R, Sarwer D, Prus-Wisniewski R. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001; 161:218–227.

    Article  CAS  Google Scholar 

  47. Poston W, Haddock C, Dill P, Thayer B, Foreyt J. Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity. Obes Res 2001; 9:552–563.

    CAS  Google Scholar 

  48. Greenway, FL, Ryan DH, Bray G, et al. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999; 7:523–531.

    CAS  Google Scholar 

  49. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 1993; 17:241–244.

    CAS  Google Scholar 

  50. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19:221–226

    CAS  Google Scholar 

  51. Drent ML, van der Veen EA. First clinical studies with orlistat: a short review. Obes Res 1995; 3(Suppl 4):623S–625S.

    CAS  Google Scholar 

  52. Finer N, James W, Kopelman P, et al. One-year treatment of obesity: a randomized double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Intern J Obes 2000; 24:306–313.

    Article  CAS  Google Scholar 

  53. Heymsfield S, Segal K, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321–1326.

    Article  CAS  Google Scholar 

  54. James W, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997; 21(Suppl 3):S24–S30.

    CAS  Google Scholar 

  55. Lindgarde F on behalf of the Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Int Med 2000; 248:245–254.

    Article  CAS  Google Scholar 

  56. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998: 352:167–172.

    Article  CAS  Google Scholar 

  57. Davidson M, Hauptman J, DiGirolamo M, Foreyt J, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281:235–242.

    Article  CAS  Google Scholar 

  58. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002; 56: 494–499.

    CAS  Google Scholar 

  59. Hanefeld M, Sachse G. Diabetes, The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diab Obes Metab 2002; 4:415–423.

    Article  CAS  Google Scholar 

  60. Kelley D, Bray G, Pi-Sunyer F, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with type 2 diabetes: a 1 year randomized controlled trial. Diabetes Care 2002; 25:1033–1041.

    Article  CAS  Google Scholar 

  61. Miles J, Leiter L, Hollander, P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25:1123–1128.

    Article  CAS  Google Scholar 

  62. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 29:1873–1878.

    Article  Google Scholar 

  63. Snider L, Malone M. Orlistat use in type 2 diabetes. Ann Pharmacother 2002; 36:1210–1218.

    Article  CAS  Google Scholar 

  64. Rissanen A, Lean M, Rossner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Dis 2003; 27:103–109.

    Article  CAS  Google Scholar 

  65. McDuffie J, Calis K, Uwaifo G, et al. Three-month tolerability of orlistat in adolescents with obesity-related co-morbid conditions. Obes Res 2002;10:642–650.

    Article  CAS  Google Scholar 

  66. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3(Suppl 4):553S–559S.

    CAS  Google Scholar 

  67. Stock MJ. Sibutramine-A review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21(Suppl 1):S25–S29.

    CAS  Google Scholar 

  68. Bray G, Greenway F. Current and potential drugs for treatment of obesity. Endocrine Reviews 1999; 20:805–875.

    Article  CAS  Google Scholar 

  69. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very low calorie diet: a randomized blinded trial of the efficacy and tolerability of Sibutramine. Amer J Med 1999; 106:179–184.

    Article  CAS  Google Scholar 

  70. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356:2119–2125.

    Article  CAS  Google Scholar 

  71. Lean MEJ: Sibutramine—a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21(Suppl 1):S30–S36.

    CAS  Google Scholar 

  72. Yanovski S, Yanovski, J. Drug therapy: obesity. N Engl J Med 2002; 346:591–602.

    Article  CAS  Google Scholar 

  73. McMahon, F, Fujioka K, Singh, B, et al. Efficacy and safety of Sibutramine in obese white and African-American patients with hypertension: a 1-year, double blind placebo controlled, multicenter trial. Arch Int Med 2000; 160:2185–2191.

    Article  CAS  Google Scholar 

  74. Wadden T, Berkowitz R, Womble L, et al. Effects of sibutramine plus orlistat in obese women following one year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8:431–437.

    CAS  Google Scholar 

  75. Berkowitz R, Wadden T, Tershakovec A, Cronquist J. Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003; 289:1805–1812.

    Article  CAS  Google Scholar 

  76. Cummings D, Shannon M. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138:389–396.

    Article  CAS  Google Scholar 

  77. Vastag B. Experimental drugs take aim at obesity. JAMA 2003; 289:1763–1764.

    Article  Google Scholar 

  78. Bray G, Tartaglia L. Medicinal strategies in the treatment of obesity. Nature 2000; 404:672–677.

    CAS  Google Scholar 

  79. Schwartz M, Woods S, Porte D, et al. Central nervous system control of food intake. Nature 2000; 404:661–671.

    CAS  Google Scholar 

  80. Woods S, Seeley R, Porte D, Schwartz M. Signals that regulate food intake and energy homeostasis. Science 1998; 280:1378–1383.

    Article  CAS  Google Scholar 

  81. Kojima M, Hosoda H, Dte Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656–660.

    Article  CAS  Google Scholar 

  82. Weigle D, Cummings D, Newby P, et al. Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. J Clin Endocrinol Metab 2003; 88:1577–1586.

    Article  CAS  Google Scholar 

  83. Nakazato M, Murakami N, Date, Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194–198.

    Article  CAS  Google Scholar 

  84. Weigle D. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab 2003; 88:2462–2469.

    Article  CAS  Google Scholar 

  85. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molec Pharmacol 2003; 63:908–14.

    Article  CAS  Google Scholar 

  86. Ravinet T, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Amer J Physiol-RegIntegrative Compar Physiol 2003; 284:R345–53.

    Google Scholar 

  87. Williams C, Kirkham T. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacol 1999; 143:315–317.

    Article  CAS  Google Scholar 

  88. Ettinger M, Littlejohn T, Schwartz S, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289:1826–1832.

    Article  CAS  Google Scholar 

  89. Huestis M, Gorelick D, Heishman S, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322–328.

    Article  CAS  Google Scholar 

  90. Vickers S, Webster, L, Wyatt A, et al. Preferential effects of the cannabinoid CB-sub-1 receptor antaonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 2003; 167:103–111.

    CAS  Google Scholar 

  91. National Task Force on the Prevention and Treatment of Obesity. Very low-calorie diets. JAMA 1993; 270:967–974.

    Article  Google Scholar 

  92. Wadden TA, Bartlett SJ. Very low calorie diets: an overview and appraisal. In: Wadden TA, VanItallie TB, eds. Treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 44–79.

    Google Scholar 

  93. Kral JG. Surgical treatment of obesity. In: Wadden TA, VanItallie TB, eds. Treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 496–506.

    Google Scholar 

  94. Brolin R. Bariatric surgery and long-term control of morbid obesity. JAMA 2002; 288: 2793–2796.

    Article  Google Scholar 

  95. Pope G, Birkmeyer J, Finlayson S. National trends in utilization and in-hospital outcomes of bariatric surgery. J Gastrointestinal Surg 2002; 6:855–860.

    Article  Google Scholar 

  96. Benotti PN, Forse RA. The role of gastric surgery in the multidisciplinary management of severe obesity. Am J Surg 1995; 169:361–367.

    Article  CAS  Google Scholar 

  97. WHO. Obesity Preventing and Managing the Global Epidemic. World Health Organization, Geneva, Switzerland, 1998.

    Google Scholar 

  98. Sjostrom C, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obesity Res 1999; 7:477–484.

    CAS  Google Scholar 

  99. Torgerson J, Sjostrom L. The Swedish Obese Subjects (SOS) Study-rationale and results. Int J Obes 2001; 25:S2–S4.

    Article  Google Scholar 

  100. Greenway S, Greenway F, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 2002; 137:1109–1117.

    Article  Google Scholar 

  101. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002; 236:554–559.

    Article  Google Scholar 

  102. Lujan J, Hernandez, Q, Frutos M, et al. Laparoscopic gastric bypass in the treatment of morbid obesity: preliminary results of a new technique. Surgical Endoscopy 2002; 16:1658–1662.

    Article  CAS  Google Scholar 

  103. Papasavas PK, Hayetian FD, Caushaj PF, et al. Outcome analysis of laparoscopic Roux-en-Y gastric bypass for morbid obesity: the first 116 cases. Surgical Endoscopy 2002; 16:1653–1657.

    Article  CAS  Google Scholar 

  104. Gould, JC, Needleman BJ, Ellison EC, et al. Evolution of minimally invasive bariatric surgery. Surgery 2002; 132:565–571.

    Article  Google Scholar 

  105. Dresel A, Kuhn JA. Establishing a laparoscopic gastric bypass program. Amer J Surg 2002; 184:617–620.

    Article  Google Scholar 

  106. Schauer P, Ikramuddin S, Hamad G, Gourash W. The learning curve for laparoscopic Roux-en-Y gastric bypass is 100 cases. Surg Endoscopy 2003; 17:212–215.

    Article  CAS  Google Scholar 

  107. Craig BM, Tseng DS. Cost-effectiveness of gastric bypass for severe obesity. Amer J Med 2002; 113:491–498.

    Article  Google Scholar 

  108. Martin LF, Tan TL, Horn JR, et al. Comparison of the costs associated with medical and surgical treatment of obesity. Surgery 1995; 118:599–607.

    Article  CAS  Google Scholar 

  109. Narbro K, Goran A, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Int Med 2002; 162:2061–2069.

    Article  Google Scholar 

  110. Klem M, Wing R, Chang C, et al. A case-control study of successful maintenance of a substantial weight loss: individuals who lost weight through surgery versus those who lost weight through non-surgical means. Int J Obes Relat Metab Disord 2000; 24:573–579.

    Article  CAS  Google Scholar 

  111. Brownell KD, Wadden TA. Etiology and treatment of obesity: understanding a serious, prevalent, and refractory disorder. J Consult Clin Psychol 1992; 60:505–517.

    Article  CAS  Google Scholar 

  112. Foreyt JP, Poston WSC, Goodrick GK. Future directions in obesity and eating disorders. Addict Behav 1996; 21:767–778.

    Article  CAS  Google Scholar 

  113. Institute of Medicine. Weighing the options: criteria for evaluating weight-management programs. National Academy Press, Washington, DC, 1995, pp. 37–63.

    Book  Google Scholar 

  114. Bender R, Trautner C, Spraul M, et al. Assessment of excess mortality in obesity. Am J Epidemiol 1998; 147:42–48.

    CAS  Google Scholar 

  115. Williamson DF, Pamuk ER. The association between weight loss and increased longevity: a review of the evidence. Ann Intern Med 1993; 119:731–736.

    CAS  Google Scholar 

  116. Fontaine, K, Redden, D, Wang, C, et al. Years of life lost due to obesity. JAMA 2003; 289:187–193.

    Article  Google Scholar 

  117. Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality: a review. Ann Intern Med 1993; 119:737–743.

    CAS  Google Scholar 

  118. Williamson, DF, Thompson, TJ, Thun, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499–1504.

    Article  CAS  Google Scholar 

  119. Williamson DF, Pamuk ER, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight U.S. white women aged 40–64 years. Am J Epidemiol 1995; 141:1128–1141.

    CAS  Google Scholar 

  120. Foster GD, Sarwer DB, Wadden TA. Psychological effects of weight cycling in obese persons: a review and research agenda. Obes Res 1997; 5:474–488.

    CAS  Google Scholar 

  121. Blair SN, Shaten J, Brownell K, et al. Body weight change, all-cause mortality, and cause-specific mortality in the Multiple Risk Factor Intervention Trial. Ann Intern Med 1993; 119:749–757.

    CAS  Google Scholar 

  122. Iribarren C, Sharp DS, Burchfiel CM, et al. Association of weight loss and weight fluctuation with mortality in Japanese American men. N Engl J Med 1995; 333:686–692.

    Article  CAS  Google Scholar 

  123. National Task Force on the Prevention and Treatment of Obesity. Weight cycling. JAMA 1994; 272:1196–1202.

    Article  Google Scholar 

  124. Venditti EM, Wing RR, Jakicic JM, et al. Weight cycling, psychological health, and binge eating in obese women. J Consult Clin Psychol 1996; 64:400–405.

    Article  CAS  Google Scholar 

  125. Foreyt JP, Brunner RL, Goodrick GK, et al. Psychological correlates of weight fluctuation. Int J Eat Disord 1995; 17:263–275.

    Article  CAS  Google Scholar 

  126. Yanovski SZ. Are anorectic agents the “magic bullet” for obesity? Arch Fam Med 1993; 2:1025–1027.

    Article  CAS  Google Scholar 

  127. Gullo SP. Food control training as a successor to dieting: a new model for weight management. In: VanItallie TB, Simonpoulos AP, eds. Obesity: new directions in assessment and management. Charles Press, Philadelphia, PA, 1995, pp. 153–171.

    Google Scholar 

  128. Perri MG. Improving maintenance of weight loss following treatment by diet and lifestyle modification. In: Wadden TA, VanItallie TB, eds. Treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 456–477.

    Google Scholar 

  129. Guy-Grand B. Long-term pharmacological treatment of obesity. In: Wadden TA, VanItallie TB, eds. Treatment of the seriously obese patient. Guilford, New York, NY, 1992, pp. 478–495.

    Google Scholar 

  130. Institute of Medicine. Weighing the options: criteria for evaluating weight-management programs. National Academy Press, Washington, DC, 1995, pp. 152–170.

    Book  Google Scholar 

  131. APA Practice Directorate. Website: (http://www.apa.org/practice/cpt2002.html).

  132. Kerns R. The new health and behavior assessment and intervention CPT codes: advancing the practice of clinical health psychology. Health Psychologist 2002; 24:10–11.

    Google Scholar 

  133. Klem M, Viteri J, Wing R. Primary prevention of weight gain for women aged 25–34: the acceptability of treatment formats. Int J Obes 2000; 24:219–225.

    Article  CAS  Google Scholar 

  134. Tate D, Wing R, Winett R. Using internet technology to deliver a behavioral weight loss program. JAMA 2001; 285:1172–1177.

    Article  CAS  Google Scholar 

  135. Fries JF, Koop, CE, Beadle CE, et al. Reducing health care costs by reducing the need and demand for medical services. N Engl J Med 1993; 329:321–325.

    Article  CAS  Google Scholar 

  136. Foreyt JP, Goodrick GK. The ultimate triumph of obesity. Lancet 1995; 346:134–135.

    Article  CAS  Google Scholar 

  137. Curb JD, Marcus EB. Body fat and obesity in Japanese Americans. Am J Clin Nutr 1991; 53:1552S–1555S.

    CAS  Google Scholar 

  138. James WPT. A public health approach to the problem of obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl. 3):S37–S45.

    Google Scholar 

  139. Lissner L, Heitman BL. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr 1995; 49:79–90.

    CAS  Google Scholar 

  140. Battle EK, Brownell KD. Confronting a rising tide of eating disorders and obesity: treatment vs. prevention and policy. Addict Behav 1996; 21:755–765.

    Article  CAS  Google Scholar 

  141. Institute of Medicine. Weighing the options: criteria for evaluating weight-management programs. National Academy Press, Washington, DC, 1995, pp. 102–117.

    Book  Google Scholar 

  142. Mokdad A, Bowman B, Ford E, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286:1195–2000.

    Article  CAS  Google Scholar 

  143. Sherwood N, Jeffrey R. The behavioral determinants of exercise: implications for physical activity interventions. Annu Rev Nut 2000; 20:21–44.

    Article  CAS  Google Scholar 

  144. US Department of Health and Human Services (USDHHS). Physical Activity and Health: a Report of the Surgeon General. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, 1996.

    Google Scholar 

  145. USDHHS. Healthy People 2010. US Government Printing Office, Washington, DC,2000. Available at Website: (http://www.healthypeople.gov).

    Google Scholar 

  146. USDHHS. Healthy people in healthy communities. Washington, DC: US Government Printing Office, 2001. Available at Website: (http://www.healthypeople.gov).

    Google Scholar 

  147. Serdula M, Mokdad A, Williamson D, et al. Prevalence of attempting weight loss and strategies for controlling weight, JAMA 1999; 282:1353–1358.

    Article  CAS  Google Scholar 

  148. Wee C, McCarthy E, Davis R, Phillips R. Physician counseling about exercise. JAMA 1999; 282:1583–1588.

    Article  CAS  Google Scholar 

  149. Grilo CM. The role of physical activity in weight loss and weight loss management. Medicine, Exercise, Nutrition, And Health 1995; 4:60–76.

    Google Scholar 

  150. Klem ML, Wing RR, McGuire MT, et al. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997; 66:239–246.

    CAS  Google Scholar 

  151. Klem M. Successful losers: The habits of individuals who have maintained long-term weight loss. Minnesota Medicine 2000; 83:43–45.

    CAS  Google Scholar 

  152. McGuire M, Wing R, Klem M, et al. Long-term maintenance of weight loss: do people who lose weight through various weight loss methods use different behaviors to maintain their weight? Int J Obes Relat Metab Disord 1998; 22:572–577.

    Article  CAS  Google Scholar 

  153. Wing R, Hill J. Successful weight loss maintenance. Ann Rev Nut 2001; 21:323–341.

    Article  CAS  Google Scholar 

  154. Orleans C, Kraft K, Marx J, McGinnis J. Why are some neighborhoods active and others not? charting a new course for research on the policy and environmental determinants of physical activity. Ann Behav Med 2003; 25: 77–79.

    Article  Google Scholar 

  155. Barlow CE, Kohl HW, Gibbons LW, et al. Physical fitness, mortality, and obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl 4):S41–S44.

    Google Scholar 

  156. Barker DJP, Hales CN, Fall CHD, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension, and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36:62–67.

    Article  CAS  Google Scholar 

  157. Dorner G, Plagemann A. Perinatal hyperinsulinism as a possible predisposing factor for diabetes mellitus, obesity, and enhanced cardiovascular risk in later life. Horm Metab Res 1994; 26:213–221.

    CAS  Google Scholar 

  158. Fall CH, Vijayakumar M, Barker DJ, et al. Weight in infancy and prevalence of coronary heart disease in adult life. BMJ 1995; 310:17–19.

    CAS  Google Scholar 

  159. Bowen DJ, Tomoyasu N, Cauce AM. The triple threat: a discussion of gender, class, and race differences in weight. Women Health 1991; 17:123–143.

    CAS  Google Scholar 

  160. Epstein LH, Valoski A, Wing RR, et al. Ten-year outcomes of behavioral family-based treatment for childhood obesity. Health Psychol 1994; 13:373–383.

    Article  CAS  Google Scholar 

  161. Burke LE, Dunbar-Jacobs J. Adherence to medication, diet, and activity recommendations: from assessment to maintenance. J Cardiovasc Nurs 1995; 9:62–79.

    CAS  Google Scholar 

  162. Kirschenbaum DS, Fitzgibbon ML. Controversy about the treatment of obesity: criticisms or challenges? Behavior Therapy 1995; 26:43–68.

    Article  Google Scholar 

  163. Anonymous. Daily dietary fat and total food-energy intakes—Third National Health and Nutrition Examination Survey, Phase 1, 1988–91. MMWR 1994; 43:116–124.

    Google Scholar 

  164. Burkitt DP, Eaton SB. Putting the wrong fuel in the tank. Nutrition 1989; 5:189–191.

    CAS  Google Scholar 

  165. Eaton SB. Humans, lipids and evolution. Lipids 1992; 27:814–820.

    Article  CAS  Google Scholar 

  166. Whitaker RC, Wright JA, Finch AJ, et al. School lunch: a comparison of the fat and cholesterol content with dietary guidelines. J Pediatr 1993; 123:857–862.

    Article  CAS  Google Scholar 

  167. Chapman N, Gordon AR, Burghardt JA. Factors affecting the fat content of National School Lunch Program lunches. Am J Clin Nutr 1995; 61(Suppl 1):199S–204S.

    CAS  Google Scholar 

  168. Jacobson MF, Brownell, KD. Small taxes on soft drinks and snack foods to promote health. Amer J Public Health 2000; 90:854–857.

    Article  CAS  Google Scholar 

  169. Saelens B, Sallis J, Frank L. Environmental correlates of walking and cycling: findings from the transportation, urban design, and planning literature. Ann Behav Med 2003; 80–91.

    Google Scholar 

  170. Poston W, Haddock C, Hughey J, et al. (2002, April). Obesity and the environment: a tale of two Kansas cities. Presentation at the Society of Behavioral Medicine’s Twenty-Third Annual Scientific Sessions, Washington, DC (Rapid Submission).

    Google Scholar 

  171. Goodman WC. The invisible woman: confronting weight prejudice in America. Carlsbad, CA: Gürze Books, 1995, pp. 18–45.

    Google Scholar 

  172. Andersen RE, Wadden TA, Bartlett SJ, et al. Relation of weight loss to changes in serum lipids and lipoproteins in obese women. Am J Clin Nutr 1995; 62:350–357.

    CAS  Google Scholar 

  173. Björntorp P. Evolution of the understanding of the role of exercise in obesity and its complications. Int J Obes Relat Metab Disord 1995; 19 (Suppl 4):S1–S4.

    Google Scholar 

  174. Wooley SC. Maelstrom revisited. Am Psychol 1995; 50:943–944.

    Article  Google Scholar 

  175. Foreyt JP, Goodrick GK. Living without dieting. New York, NY: Warner Books, 1994, pp. 15–126.

    Google Scholar 

  176. O’Neil PM, Smith CF, Foster GD, Anderson DA. The perceived relative worth of reaching and maintaining goal weight. Int J Obes 2000; 24:1069–1076.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, University of Missouri-Kansas City, Kansas City, MO

    Lisa Terre PhD & Walker S. C. Poston II PhD, MPH

  2. Mid America Heart Institute, Kansas City, MO

    Walker S. C. Poston II PhD, MPH

  3. Behavioral Medicine Research Center, Department of Medicine, Baylor College of Medicine, Houston, TX

    John P. Foreyt PhD

Authors
  1. Lisa Terre PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walker S. C. Poston II PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John P. Foreyt PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Toxicology, Indiana University School of Medicine and PRN Consulting, Indianapolis, IN

    David J. Goldstein MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc.,Totowa,NJ

About this chapter

Cite this chapter

Terre, L., Poston , W.S.C., Foreyt, J.P. (2005). Overview and the Future of Obesity Treatment. In: Goldstein, D.J. (eds) The Management of Eating Disorders and Obesity. Nutrition and Health. Humana Press. https://doi.org/10.1385/1-59259-865-X:161

Download citation

  • DOI: https://doi.org/10.1385/1-59259-865-X:161

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-341-1

  • Online ISBN: 978-1-59259-865-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation